Affiliation:
1. Chuvash State University
Abstract
Atrial fibrillation remains a significant public health problem worldwide to this day, and in combination with valvular heart disease it worsens the patient's prognosis. in patients with prosthetic heart valves, the use of anticoagulants is a prerequisite to prevent thromboembolic complications. Indirect anticoagulants, in particular, Warfarin, remain the front-line therapy. This article presents a clinical case of hypersensitivity to Warfarin in a patient of the Chuvash population with an implanted mitral valve. in the postoperative period, difficulties were identified to control the target international normalized ratio. the article examines the factors that could contribute to an increase in sensitivity to Warfarin in this patient. Current literature data on polymorphisms of the CYP2C9 and VKORC1 genes that predetermine hypersensitivity to Warfarin and their prevalence are presented. the clinical case demonstrates the prospects for introducing pharmacogenetic testing as a tool that increases the effectiveness and safety of pharmacotherapy in certain ethnic groups.
Publisher
I.N. Ulianov Chuvash State University
Subject
Management Science and Operations Research,Mechanical Engineering,Energy Engineering and Power Technology
Reference13 articles.
1. Sychev D.A., Antonov I.M., Ignat’ev I.V. et al Antikoagulyantnoe deistvie i bez-opasnost’ primeneniya varfarina pri ego dozirovanii, osnovannom na rezul’tatakh farmakogeneticheskogo testirovaniya: rezul’taty pervogo rossiiskogo prospektivnogo issledovaniya [Anticoagulant effect and safety of warfarin in its dosing based on the results of pharmacogenetic testing: results of the first Russian prospective study]. Kardiologiya, 2010, no. 5. pp. 42–46.
2. Bairova T.A., Sambyalova A.Yu., Rychkova L.V. et al. Farmakogeneticheskii algoritm dozirovaniya varfarina v rossiiskoi populyatsii [Pharmacogenetic algorithm of warfarin dosing in the Russian population]. Acta biomedica scientifica, 2019, no. 4(3). pp. 40–44.
3. Georgieva K.S., Pavlova S.I., Bogdanova S.M. et al. Klinicheskii sluchai personalizatsii terapii varfarinom: farmakogeneticheskoe te-stirovanie i mezhlekarstvennoe vzaimodeistvie [Clinical case of personalization of warfarin therapy: pharmacogenetic testing and drug-drug interaction]. Farmakogenetika i farmakogenomika, 2020, 2, pp. 30–31.
4. Mirzaev K.B., Fedorinov D.S., Ivashchenko D.V., Sychev D.A. Mul’tietnicheskii analiz kardiologicheskikh farmakogeneticheskikh markerov genov tsitokhroma R450 i membrannykh transporterov v rossiiskoi populyatsii [Multiethnic analysis of cardiological pharmacogenetic markers of cytochrome P450 genes and membrane transporters in the Russian population]. Ratsional’naya Farmakoterapiya v kardiologii, 2019, no. 15(3), pp. 393–406.
5. Rumyantsev N.A., Sychev D.A., Kukes V.G. et al. Opyt individualizatsii primeneniya i dozirovaniya peroral’nykh antikoagulyantov v usloviyakh funktsionirovaniya tsentra personalizirovannoi meditsiny [Experience of individualization of the use and dosing of oral anticoagulants in the functioning of the center for personalized medicine]. Kazanskii meditsinskii zhurnal, 2015, 96(6), pp. 1065–1068.